Bictegravir-Lenacapavir STR: Effective & Preferred HIV-1 Treatment Option

For people living with HIV who find themselves on complex, multi-tablet treatment regimens, a new single-tablet option is showing promising results. Data presented at the Conference on Retroviruses and Infectious Diseases (CROI) 2026 indicate that switching to a combination of bictegravir and lenacapavir maintains viral suppression with a safety profile comparable to existing treatments. This development offers a potential simplification of care for individuals who may face challenges adhering to more complicated medication schedules, or who have developed resistance to other therapies.

ARTISTRY-1: A Shift Towards Simplified HIV Treatment

The findings stem from two Phase 3 trials, ARTISTRY-1 and ARTISTRY-2, with ARTISTRY-1 being the focus of initial publication in The Lancet and detailed in a report on PubMed. ARTISTRY-1 was a randomized, open-label trial involving 557 participants with virologically suppressed HIV who were already on complex antiretroviral regimens. Participants were assigned either to switch to the once-daily bictegravir 75mg/lenacapavir 50mg single-tablet regimen (BIC/LEN) or to continue their existing complex regimen. The primary outcome measured was the proportion of participants who experienced a rebound in viral load (reaching 50 copies per mL or higher) at week 48.

The results demonstrated non-inferiority: just 1% of participants in the BIC/LEN group and 1% in the complex regimen group experienced viral rebound. This difference of -0.3% fell well within the pre-defined margin for non-inferiority, meaning the new single-tablet regimen performed at least as well as the established, more complicated treatments. Notably, the trial enrolled participants with a long history of HIV treatment – a median treatment duration of 28 years – and who were taking a median of three pills per day, highlighting the potential benefit for those with long-term, challenging treatment histories.

Understanding the Components: Bictegravir and Lenacapavir

Bictegravir is an integrase strand transfer inhibitor (INSTI), a class of drugs widely used in HIV treatment. INSTIs work by blocking the viral enzyme integrase, which HIV needs to insert its genetic material into the host cell’s DNA. Bictegravir is already a component of several commonly prescribed single-tablet regimens and is known for its high barrier to resistance. Lenacapavir, still, represents a novel approach. It’s a first-in-class capsid inhibitor, meaning it disrupts a different stage of the HIV lifecycle – the assembly of the viral capsid, the protein shell that protects the virus’s genetic material. This dual-action approach, combining a well-established INSTI with a new class of drug, is designed to provide durable viral suppression.

Who Benefits from This New Option?

The ARTISTRY-1 trial specifically targeted individuals already on complex regimens. This includes people who have developed resistance to certain antiretroviral drugs, those with drug-drug interactions that limit their treatment options, or those with medical conditions that make it difficult to tolerate certain medications. For these individuals, simplifying their treatment to a single daily pill could significantly improve adherence and quality of life. However, it’s vital to note that this study focused on individuals who were already virally suppressed. The efficacy and safety of BIC/LEN in treatment-naive individuals (those starting HIV treatment for the first time) are still under investigation.

Trial Design and Limitations

The open-label design of ARTISTRY-1 – meaning both participants and researchers knew which treatment was being administered – introduces a potential for bias. While the researchers took steps to minimize this, it’s a limitation to consider. The trial followed participants for 48 weeks. Longer-term data will be crucial to assess the durability of viral suppression and the emergence of any potential resistance. The study also did not specifically assess the impact of the switch on patient-reported outcomes beyond adherence, so the full extent of the benefit in terms of quality of life requires further investigation. Gilead Sciences, the manufacturer of BIC/LEN, announced the results, which is also a factor to consider when interpreting the findings.

What Does This Mean for HIV Treatment?

The success of the ARTISTRY-1 trial signals a continued evolution in HIV treatment. The move towards simpler, more tolerable regimens is a key goal, as it can improve adherence, reduce the risk of treatment failure, and ultimately enhance the overall health and well-being of people living with HIV. The combination of bictegravir and lenacapavir offers a new tool for clinicians to optimize treatment for individuals facing challenges with existing regimens. The data from both ARTISTRY-1 and ARTISTRY-2 will inform regulatory filings, potentially paving the way for the approval of BIC/LEN as a new treatment option.

Looking Ahead: Regulatory Review and Potential Access

Gilead Sciences has indicated its intention to submit the ARTISTRY-1 and ARTISTRY-2 data to regulatory authorities, including the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA). The review process typically involves a thorough evaluation of the trial data, manufacturing processes, and safety profile. If approved, BIC/LEN would become another valuable addition to the arsenal of HIV treatments available. The timeline for potential approval and access remains uncertain, but the positive trial results represent a significant step forward. Continued monitoring of long-term outcomes and potential resistance patterns will be essential as this new regimen becomes more widely used.